The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy
Open accessAbstract
BACKGROUND: Transcriptionally silent human immunodeficiency virus type 1 (HIV-1) DNA persists in resting memory CD4(+) T cells despite antiretroviral therapy. In a primary cell model, the antialcoholism drug disulfiram has been shown to induce HIV-1 transcription in latently infected resting memory CD4(+) T cells at concentrations achieved in vivo. METHODS: We conducted a single-arm pilot study to evaluate whether 500 mg of disulfiram administered daily for 14 days to HIV-1-infected individuals on stable suppressive antiretroviral therapy would result in reversal of HIV-1 latency with a concomitant transient increase in residual viremia or depletion of the latent reservoir in resting memory CD4(+) T cells. RESULTS: Disulfiram was safe and well tolerated. There was a high level of subject-to-subject variability in plasma disulfiram levels. The latent reservoir did not change significantly (1.16-fold change; 95% confidence interval [CI], .70- to 1.92-fold; P = .56). During disulfiram administration, residual viremia did not change significantly compared to baseline (1.53-fold; 95% CI, .88- to 2.69-fold; P = .13), although residual viremia was estimated to increase by 1.88-fold compared to baseline during the postdosing period (95% CI, 1.03- to 3.43-fold; P = .04). In a post hoc analysis, a rapid and transient increase in viremia was noted in a subset of individuals (n = 6) with immediate postdose sampling (HIV-1 RNA increase, 2.96-fold; 95% CI, 1.29- to 6.81-fold; P = .01). CONCLUSIONS: Administration of disulfiram to patients on antiretroviral therapy does not reduce the size of the latent reservoir. A possible dose-related effect on residual viremia supports future studies assessing the impact of higher doses on HIV-1 production. Disulfiram affects relevant signaling pathways and can be safely administered, supporting future studies of this drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., Quinn, T. C., Chadwick, K., Margolick, J., Brookmeyer, R., et al. (1997) · Science · doi:10.1126/science.278.5341.1295 · Cited by 3,098
Self-citationRecovery of replication-competent HIV despite prolonged suppression of plasma viremia
Wong, J. K., Hezareh, M., Günthard, H. F., Havlir, D. V., Ignacio, C. C., Spina, C. A., & Richman, D. D. (1997) · Science · doi:10.1126/science.278.5341.1291 · Cited by 2,186
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
Chun, T.-W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J. A., Taylor, H., Hermankova, M., Chadwick, K., Margolick, J., Quinn, T. C., et al. (1997) · Nature · doi:10.1038/387183a0 · Cited by 2,050
Self-citationSiliciano, J. D., Kajdas, J., Finzi, D., Quinn, T. C., Chadwick, K., Margolick, J. B., Kovacs, C., Gange, S. J., & Siliciano, R. F. (2003) · Nature Medicine · doi:10.1038/nm880 · Cited by 1,703
Self-citationDisulfiram Treatment of Alcoholism: A Veterans Administration Cooperative Study
Fuller, R. K. (1986) · JAMA · doi:10.1001/jama.1986.03380110055026 · Cited by 431
The Status of Disulfiram: A Half of a Century Later
Suh, J. J., Pettinati, H. M., Kampman, K. M., & O'Brien, C. P. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000222512.25649.08 · Cited by 382
Doyon, G., Zerbato, J., Mellors, J. W., & Sluis-Cremer, N. (2013) · AIDS · doi:10.1097/qad.0b013e3283570620 · Cited by 107
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Bullen, C. K., Laird, G. M., Durand, C. M., Siliciano, J. D., & Siliciano, R. F. (2014) · Nature Medicine · doi:10.1038/nm.3489 · Cited by 488
Self-citationLynch, R. M., Boritz, E., Coates, E. E., DeZure, A., Madden, P., Costner, P., Enama, M. E., Plummer, S., Holman, L., Hendel, C. S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5752 · Cited by 465
Getting the “Kill” into “Shock and Kill”: Strategies to Eliminate Latent HIV
Kim, Y., Anderson, J. L., & Lewin, S. R. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2017.12.004 · Cited by 414
Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations
Laird, G. M., Bullen, C. K., Rosenbloom, D. I. S., Martin, A. R., Hill, A. L., Durand, C. M., Siliciano, J. D., & Siliciano, R. F. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80142 · Cited by 391
Self-citation
Metadata
- Authors
- Spivak, A. M., Andrade, A., Eisele, E., Hoh, R., Bacchetti, P., Bumpus, N. N., Emad, F., Buckheit, R., McCance-Katz, E. F., Lai, J., Kennedy, M., Chander, G., Siliciano, R. F., Siliciano, J. D., & Deeks, S. G.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-12-12
- Volume
- 58
- Issue
- 6
- Pages
- 883-890
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2151980311
- Cited by
- 200
- References
- 7
- FWCI
- 8.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy. https://app.cochat.ai/papers/10.1093/cid/cit813
- The paper
- Spivak, A. M., Andrade, A., Eisele, E., Hoh, R., Bacchetti, P., Bumpus, N. N., Emad, F., Buckheit, R., McCance-Katz, E. F., Lai, J., Kennedy, M., Chander, G., Siliciano, R. F., Siliciano, J. D., & Deeks, S. G. (2014). A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy. Clinical Infectious Diseases. https://doi.org/10.1093/cid/cit813
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.